Cognitive Behavioral Therapy Plus Drug Treatment for Obsessive Compulsive Disorder
Aug1
CBT Augmentation for SRI Pharmacotherapy in OCD
3 other identifiers
interventional
136
1 country
2
Brief Summary
This study will evaluate the effectiveness of two cognitive behavioral therapies (CBTs) in treating obsessive compulsive disorder (OCD) in patients who are taking medication but still have residual symptoms.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Aug 2000
Longer than P75 for not_applicable
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 1, 2000
CompletedFirst Submitted
Initial submission to the registry
September 13, 2002
CompletedFirst Posted
Study publicly available on registry
September 17, 2002
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2007
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2007
CompletedApril 23, 2014
October 1, 2012
6.4 years
September 13, 2002
April 22, 2014
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Obsessive-compulsive symptoms measured at Month 2
2 months
Secondary Outcomes (1)
General functioning measured at Month 2
2 months
Study Arms (2)
Exposure and Ritual Prevention
EXPERIMENTALExposure and Ritual Prevention Therapy
Stress Management
ACTIVE COMPARATORStress Management Therapy
Interventions
Eligibility Criteria
You may qualify if:
- Obsessive-Compulsive Disorder (OCD) diagnosis
- Currently taking a serotonin reuptake inhibitor (SRI, i.e. clomipramine, fluoxetine, fluvoxamine, paroxetine, sertraline, or citalopram) for OCD
You may not qualify if:
- Medical or psychiatric conditions that would make participation in the study hazardous
- Intensive cognitive-behavioral therapy while on an adequate dose and duration of an SRI for OCD
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
New York State Psychiactic Institute, Anxiety Disorders Clinic
New York, New York, 10032, United States
University of Pennsylvania Center for the Treatment and Study of Anxiety
Philadelphia, Pennsylvania, 19104, United States
Related Publications (2)
Farris SG, McLean CP, Van Meter PE, Simpson HB, Foa EB. Treatment response, symptom remission, and wellness in obsessive-compulsive disorder. J Clin Psychiatry. 2013 Jul;74(7):685-90. doi: 10.4088/JCP.12m07789.
PMID: 23945445DERIVEDFoa EB, Simpson HB, Liebowitz MR, Powers MB, Rosenfield D, Cahill SP, Campeas R, Franklin M, Hahn CG, Hembree EA, Huppert JD, Schmidt AB, Vermes D, Williams MT. Six-month follow-up of a randomized controlled trial augmenting serotonin reuptake inhibitor treatment with exposure and ritual prevention for obsessive-compulsive disorder. J Clin Psychiatry. 2013 May;74(5):464-9. doi: 10.4088/JCP.12m08017.
PMID: 23759449DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Michael Liebowitz, MD
New York State Psychiatric Institute
- PRINCIPAL INVESTIGATOR
Edna Foa, MD
University of Pennsylvania
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 13, 2002
First Posted
September 17, 2002
Study Start
August 1, 2000
Primary Completion
January 1, 2007
Study Completion
January 1, 2007
Last Updated
April 23, 2014
Record last verified: 2012-10